Mechanistic investigations further revealed that the positive feedback loop within the FGFR1-driven PLK1/STAT3 signaling pathway serves as a critical regulatory node mediating acquired resistance to EGFR-TKI therapy in NSCLC. The gene discussed is STAT3; the disease is non-small cell lung carcinoma.